Answers are grounded in this paper and cite their sources.
In a large real-world cohort of vedolizumab maintenance concentrations, IBD patients with remission defined by objective measures [CRP and endoscopy] had significantly higher trough vedolizumab concentrations and immunogenicity was uncommon.
No takes yet. Share an insight, caveat, or question.
Ungaro et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: